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Enhanced β-adrenergic signalling underlies
an age-dependent beneﬁcial metabolic effect
of PI3K p110α inactivation in adipose tissue
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Christian Dani4, Antonio Vidal-Puig2,3 & Lazaros C. Foukas 1
The insulin/IGF-1 signalling pathway is a key regulator of metabolism and the rate of ageing.
We previously documented that systemic inactivation of phosphoinositide 3-kinase (PI3K)
p110α, the principal PI3K isoform that positively regulates insulin signalling, results in a
beneﬁcial metabolic effect in aged mice. Here we demonstrate that deletion of p110α
speciﬁcally in the adipose tissue leads to less fat accumulation over a signiﬁcant part of adult
life and allows the maintenance of normal glucose tolerance despite insulin resistance.
This effect of p110α inactivation is due to a potentiating effect on β-adrenergic signalling,
which leads to increased catecholamine-induced energy expenditure in the adipose tissue.
Our ﬁndings provide a paradigm of how partial inactivation of an essential component of the
insulin signalling pathway can have an overall beneﬁcial metabolic effect and suggest that
PI3K inhibition could potentiate the effect of β-adrenergic agonists in the treatment of obesity
and its associated comorbidities.
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Interventions to increase the lifespan and healthspan oforganisms have been the subject of intense research efforts.Loss-of-function mutations in components of the insulin/IGF-
1 signalling (IIS) pathway have long been known to have a life-
and healthspan extending effect in diverse model organisms1.
The fact that inactivating mutations in a pathway essential for
regulation of metabolic physiology extend lifespan is seemingly
paradoxical and has been referred to as the insulin paradox2.
Although evolutionary theories have been evoked to explain the
phenomenon of lifespan extension through loss-of-function
mutations in essential genetic pathways such as the IIS,
mechanistic insights as to how this is achieved at the molecular
level have only recently started to emerge3,4.
A number of genetic and other interventions that extend life-
span/healthspan have also beneﬁcial effects on metabolic phy-
siology, highlighting the interconnectedness of metabolism and
ageing5. Prime examples of gene mutations that extend lifespan
and improve glucose and lipid homoeostasis in old mice are
mutations in the growth hormone/IGF-1 signalling axis in
hypopituitary dwarf long-lived mutant mice6. Furthermore, cal-
orie restriction, the best known intervention to extend lifespan in
a number of species, has also profound beneﬁcial metabolic
effects, manifested as improved insulin sensitivity and glucose
homoeostasis in calorie restricted mice7.
In the context of interventions shown to affect both lifespan
and metabolism, the adipose tissue has a prominent role. The
adipose tissue is an important organ in the regulation of energy
homoeostasis8. Moreover, the adipose tissue has been shown to
play an important role in the lifespan-extending effects of insulin
pathway downregulation. A seminal ﬁnding in this regard has
been the demonstration that adipose tissue-speciﬁc insulin
receptor knockout mice (FIRKO) display extended longevity and
they are also protected against age-related metabolic pathologies9.
We and others have documented that p110α is the key PI3K
isoform in the insulin signalling pathway10,11. We recently
reported that global partial inactivation of p110α has an age-
dependent beneﬁcial effect on metabolism and causes a modest
increase in lifespan12. To gain further insights into the mechan-
ism underlying these effects, we assessed the role of the adipose
tissue in the beneﬁcial metabolic impact seen upon global p110α
inactivation. To this end, we inactivated p110α speciﬁcally in the
mouse adipose tissue by Cre/loxP approaches and characterised
the metabolic proﬁles of these mice over the course of ageing,
which is one of the most physiologically relevant stresses an
experimental model can be subjected to. We report here that
partial inactivation of p110α potentiates β-adrenergic signalling
in the adipose tissue. This results in enhanced catecholamine-
induced energy expenditure (EE), which counteracts the effects of
insulin resistance thus preserving normal glucose homoeostasis
over the course of ageing. These ﬁndings have clear implications
for the development of therapeutic interventions for age-related
obesity and associated comorbidities.
Results
p110α deletion in adipose tissue causes insulin resistance. We
applied Cre/loxP-mediated conditional gene deletion to inactivate
p110α in the adipose tissue of mice by crossing conditionally
targeted p110α mice (p110αFLOX)13 with a transgenic line
expressing Cre under control of the adiponectin promoter
(Adipoq–Cre)14, which is more speciﬁc for deletion in the adipose
tissue than the earlier reported aP2–Cre line15. We isolated
metabolic tissues from mice expressing the Adipoq–Cre transgene
(p110αDEL) or not (p110αFLOX), and assessed p110α protein
expression by immunoblot analysis. Signiﬁcant reduction of
p110α protein expression was only seen in the white and brown
adipose tissues (WAT and BAT) of p110αDEL mice, with a
reduction of an average of 70% (WAT) and 90% (BAT), com-
pared to the expression levels in p110αFLOX littermates (Fig. 1a, b
and Supplementary Fig. 1). The expression of p110β, the other
broadly expressed PI3K isoform, as well as that of the p85
regulatory subunit was not affected under these conditions in
p110αDEL mice.
We next tested insulin sensitivity in metabolic tissues of
approximately 1-year-old mice by injecting insulin and assessing
PI3K activity and Akt phosphorylation as readouts of insulin
pathway activation. Consistent with the previously demonstrated
role of p110α in insulin receptor signalling10,11, the PI3K activity
associated with IRS-1 immunoprecipitates was signiﬁcantly
reduced in visceral (epididymal) WAT (eWAT) of p110αDEL
mice (Fig. 1c). In line with this, insulin-induced Akt phosphor-
ylation was also signiﬁcantly impaired in eWAT, but only
marginally affected in iWAT and BAT isolated from p110αDEL
mice (Fig. 1d). Akt phosphorylation was impaired to a lower
extent also in the liver and skeletal muscle of p110αDEL mice
(Supplementary Fig. 2), indicating the development of systemic
insulin resistance. This was further corroborated by
hyperinsulinemic–euglycemic clamp experiments in 20-week-
old mice that revealed profound systemic insulin resistance at this
age point, as evidenced by an impaired rate of glucose
disappearance, increased hepatic glucose production and elevated
free fatty acids in the plasma in p110αDEL mice (Fig. 1e) under
clamp conditions. Notably, the rate of glucose disappearance at
basal level was slightly elevated in p110αDEL mice, which suggests
that p110αDEL mice may have a higher basal metabolic rate under
clamp conditions.
p110αDEL mice maintain normal glucose tolerance over ageing.
We assessed the metabolic proﬁle of p110αDEL mice by per-
forming glucose tolerance and insulin tolerance tests over a
number of time points ranging from 3 to 24 months of age. In
line with the impaired insulin signalling in metabolic tissues and
hyperinsulinemic–euglycemic clamp studies (Fig. 1d, e and Sup-
plementary Fig. 2), p110αDEL mice displayed systemic insulin
resistance at all of the time points tested (Fig. 2a and Supple-
mentary Fig. 3). However, glucose tolerance was essentially
unaffected throughout the life course. The lack of any effect seen
in mice expressing only Adipoq–Cre, and lacking targeted p110α
alleles, under the same experimental conditions, attests that these
phenotypes can conﬁdently be attributed to the deletion of p110α
alleles (Supplementary Fig. 4). A number of hormones and
cytokines and lipid proﬁles tested in the plasma of fasted one year
old mice did not show any prominent differences, with the
exception of substantially reduced insulin and leptin and slightly
reduced adiponectin, and increased total cholesterol in the plasma
of male p110αDEL mice (Fig. 2b–d). Notably, β-AR agonists have
previously been reported to reduce production and secretion of
adiponectin from the adipose tissue16. As both leptin and adi-
ponectin are known to inﬂuence insulin sensitivity of metabolic
tissues, reduced levels of leptin and adiponectin might play a role
in the development of insulin resistance in liver and skeletal
muscle, as seen in p110αDEL mice (Supplementary Fig. 2). Also,
the differential impact of p110α inactivation on fasting insulin
levels between male and female mice (Fig. 2b) suggests a sexually
dimorphic phenotypic effect. Sex differences in the function of
the adipose tissue are well-known in both mice and humans17,18.
Such effects could account for a differential impact of p110α
inactivation on insulin sensitivity and thus on fasting insulin
levels between two sexes at the age point of this measurement.
ITTs were also in line with female p110αDEL mice being sub-
stantially more insulin resistant than their control littermates, in
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contrast to male mice, at this age point of 12 months (Supple-
mentary Fig. 3).
When mice were subjected to high-fat feeding (45% calories
derived from fat), weight gain was identical between the two
genotypes (Fig. 3a). However, high-fat fed p110αDEL mice were
signiﬁcantly more glucose tolerant despite being as insulin
sensitive as p110αFLOX littermates (Fig. 3b, c). To gain further
insight into this unexpected effect of p110α inactivation, mice
were subjected to a tissue-speciﬁc glucose uptake assay over a
glucose tolerance test. We found that the BAT of p110αDEL mice
cleared approximately twice as much glucose from the circulation
as p110αFLOX littermates (Fig. 3d). No signiﬁcant differences
were detected in other organs, with the exception of visceral
WAT, which in p110αDEL mice cleared half as much glucose as
control littermates. High-fat feeding is known to activate BAT
and increase expression of UCP119. Consistent with higher BAT
activation in p110αDEL mice, we found that UCP1 protein
expression was higher in p110αDEL mice at basal level and
remained higher upon high-fat feeding over 4 weeks (Fig. 3e, f
and Supplementary Fig. 5). These data suggest that enhanced-
BAT activity can counter the effects of insulin resistance on
glucose homoeostasis of p110αDEL mice.
p110α inactivation potentiates β-adrenergic/cAMP signalling.
Since it is well-established that catecholamine stimulation of
adrenergic signalling regulates glucose and lipid metabolism in
BAT20, the enhanced glucose clearance in the face of insulin
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Fig. 1 Adipose tissue-speciﬁc p110αDEL mice are insulin resistant. a Representative immunoblot analysis of p110α protein levels in homogenates of
metabolic tissues isolated from approximately 1.5-year-old male mice carrying or not the Adipoq–Cre transgene. Blots were also probed for the widely
expressed p110β isoform and the PI3K regulatory subunit p85. Vinculin was probed as loading control. SM skeletal muscle (gastrocnemius), WAT white
adipose tissue (epididymal), BAT brown adipose tissue (interscapular). b Semi-quantitative data for p110α expression in WAT and BAT (n= 6 mice per
genotype). The respective blots are shown in Supplementary Fig. 1. c, d One-year-old mice (n= 3 per genotype) were injected intraperitoneally with 100
mU g−1 of insulin. After 30min, tissues were excised and snap frozen. c Adipose tissue (epididymal) lysates were immunoprecipitated with IRS-1
antibodies and assayed for associated PI3K lipid kinase activity. d Immunoblot analysis of adipose tissue (epididymal, eWAT; inguinal, iWAT; interscapular
brown, BAT) lysates probed for Akt T308 phosphorylation. Each lane represents an individual mouse. e Hyperinsulinemic–euglycemic clamp analysis in
20-week-old female mice. Rate of glucose disappearance (RD), glucose infusion rate (GIR) and hepatic glucose production (HGP) at the hyperinsulinemic
state and plasma levels of non-esteriﬁed fatty acids (NEFA) are shown. Average body weights: 21.7 and 21.6 g for p110aDEL and p110aFLOX mice (n= 8 per
genotype), respectively. Data are presented as mean ± SEM. Statistical analysis: unpaired two-tailed t test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Fig. 2 Insulin resistant p110αDEL mice maintain normal glucose tolerance over ageing. a Cohorts of p110αDEL and p110αFLOX male mice were subjected to
intraperitoneal glucose and insulin tolerance tests at various time points over ageing. For glucose tolerance test a bolus of glucose (2 g per kg of body
weight) was injected intraperitoneally. Insulin doses were adjusted according to the age of the mice (0.75 U kg−1 for 3-month-old and 2 U kg−1 for 18- and
24-month-old). n= 8 per genotype at 3 months, 16 per genotype at 18 months, 14 per genotype at 24 months. AUC, area under curve. Additional age
points and data for females are shown in Supplementary Fig. 3. b Fasting plasma levels of metabolic hormones in 1-year-old p110αDEL and p110αFLOX mice.
n (p110αFLOX/p110αDEL), Insulin: Female, 9/8; Male, 4/5. Leptin: Female, 8/8; Male, 7/10. Adiponectin: Female, 8/8; Male, 10/10. c Fasting plasma levels
of pro-inﬂammatory cytokines (IL6 and TNFa) in 1-year-old p110αDEL and p110αFLOX mice. n (p110αFLOX/p110αDEL), IL-6: Female, 6/7; Male, 6/9. TNFα:
Female, 8/8; Male, 7/7. d Fasting plasma levels of lipids (total cholesterol, free fatty acids and triglycerides) in 1-year-old p110αDEL and p110αFLOX mice.
n (p110αFLOX/p110αDEL), Cholesterol: Female, 8/7; Male, 3/4. FFAs: Female, 10/9; Male, 4/5. Triglycerides: Female, 8/9; Male, 10/9. n (p110αFLOX/
p110αDEL), Cholesterol: Female, 8/7; Male, 3/4. FFAs: Female, 10/9; Male, 4/5. Triglycerides: Female, 8/9; Male, 10/9. Data are presented as mean ± SEM.
Statistical analyses: Unpaired two-tailed t test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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resistance prompted us to investigate the impact of p110α inacti-
vation on the activity of adrenergic pathways in response to
catecholamine stimulation. Furthermore, adrenergic pathways
control fat metabolism by modulating lipolysis in adipose tissues21.
β-Adrenergic receptors (β-ARs) activate adenylylcyclase through
coupling to Gs subunits of heterotrimeric G proteins, resulting
in the elevation of intracellular levels of cAMP and activation of
its effector molecules, notably of protein kinase A (PKA).
Explants from subcutaneous (inguinal) and visceral adipose
tissue were stimulated with the synthetic β-AR agonist isoproter-
enol or the natural catecholamine norepinephrine. As readouts of
β-AR/cAMP pathway activation, we assessed phosphorylation
of hormone sensitive lipase (HSL), perilipin and cAMP response
element binding (CREB) protein, all of which are targets of PKA
in the adrenergic pathway in adipocytes. Tissue explants isolated
from subcutaneous adipose tissue of p110αDEL mice, as well as
those isolated from p110αFLOX mice and treated with the p110α
selective inhibitor A6622, displayed enhanced sensitivity to β-AR
stimulation by both isoproterenol (Fig. 4a, b) and norepinephrine
(Supplementary Fig. 6a, b). However, a similar effect was not
the case in explants isolated from visceral adipose tissue.
Consistent with the observed increase in the phosphorylation of
lipolysis regulatory molecules upon p110α inactivation, release
of glycerol, which provides an index of the rate of lipolysis
(Fig. 4c and Supplementary Fig. 6c), and intracellular cAMP
levels (Fig. 4d and Supplementary Fig. 6d) were found to be
increased in the subcutaneous adipose tissue of both p110αDEL
mice and that of p110αFLOX mice treated with A66.
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Since differences in the expression of various adrenergic
receptor classes and subtypes have been reported between mouse
and human adipose tissue23, we tested whether inhibition of
p110α has a similar potentiating effect on adipocytes differ-
entiated from human multipotent adipose-derived stem
(hMADS) cells24. As with mouse adipocytes, treatment of
hMADS cell-derived adipocytes with A66 resulted in potentiation
of signalling induced by a number of β-AR agonists (Fig. 4e).
Mechanism of adrenergic signalling enhancement. We sought
to gain further insights in the molecular mechanism underlying
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the potentiation of adrenergic signalling by p110α inhibition. To
this end, we probed the levels of β-AR subtype expression in
adipose tissues of p110αFLOX and p110αDEL mice. We found no
signiﬁcant differences in the expression of the various β-AR
subtypes among the different depots tested (Supplementary
Fig. 7). At the level of PI3K isoform expression, we observed
similar levels of expression of p110α between iWAT and vWAT,
but a tendency for higher level of p110β in iWAT compared to
vWAT (Supplementary Fig. 7). This is consistent with the milder
effect of p110α deletion on insulin sensitivity in iWAT compared
to vWAT (Fig. 1), as higher levels of p110β could partially
compensate for p110α deﬁciency in iWAT.
Insulin exerts its anti-lipolytic action mainly, though not
exclusively, through PI3K/Akt-mediated phosphorylation and
activation of the cAMP degrading enzyme phosphodiesterase
3B (PDE3B)25,26. We tested whether β-adrenergic stimulation
can also activate Akt phosphorylation in iWAT and vWAT. We
found that isoproterenol stimulation induced a substantial
increase in Akt phosphorylation in both iWAT and vWAT
explants (Fig. 5a). We also tested immortalised brown adipocytes
and BAT explants derived from p110αFLOX mice. Similar to
iWAT, inhibition of p110α in brown adipocytes (Fig. 5b) and
in BAT explants (Fig. 5c) potentiated NE-stimulated (immorta-
lised brown adipocytes) or ISO-stimulated (BAT explants)
adrenergic signalling, as assessed by phosphorylation of HSL
and of perilipin. p110α inhibition also potentiated phosphoryla-
tion of p38 MAPK, which has previously been shown to be an
important mediator of cAMP-dependent induction of UCP1
expression in brown adipocytes27. Similar to WAT, NE-
stimulated Akt phosphorylation in brown adipocytes in a PI3K
dependent manner (Fig. 5d). Notably, the effect of p110α
inhibitor A66 on Akt phosphorylation in brown adipocytes was
substantially lower than that in WAT and a much stronger effect
was achieved upon combined treatment with A66 and a p110β-
selective inhibitor (TGX221). This ﬁnding suggests that in
addition to p110α, the other broadly expressed PI3K isoform,
p110β, plays a role in NE-stimulated PI3K signalling in BAT.
Consistent with reduced Akt activation, inhibition of PI3K
reduced NE-stimulated phosphodiesterase activity in extracts of
p110αFLOX or p110αDEL adipocytes (Fig. 5e). In this regard, our
data are consistent with the previously reported catecholamine-
induced phosphorylation of Akt and PDE3B activation in
adipocytes28. Since long-term insulin and catecholamine treat-
ment has previously been shown to alter PDE3B expression
levels29, we also tested whether reduced expression of PDE3B
might account for enhanced adrenergic signalling in p110αDEL
adipocytes. However, protein levels of PDE3B were only
marginally lower in extracts of p110αDEL iWAT (Supplementary
Fig. 8). Furthermore, in line with previous reports30, we found
that activation of PI3K in the context of β-AR signalling is likely
mediated through the key cAMP effector EPAC, as treatment of
brown adipocytes with the EPAC inhibitor ESI09 tended to
reduce NE-stimulated Akt phosphorylation (Fig. 5d) and
prevented NE stimulation of phosphodiesterase activity (Fig. 5e).
In summary, adrenergic stimulation activates two opposing
activities in the adipose tissue: adenylylcyclase that produces
cAMP and stimulates the PKA pathway and phosphodiesterase
that degrades cAMP. Therefore, inhibition of p110α can be
potentiating adrenergic signalling by limiting the concomitant
activation of PDE activity upon adrenergic stimulation (Fig. 5f).
Consistent with this, inhibition of p110α with A66 fails to
increase adrenergic signalling above the level attained through
treatment with the general phosphodiesterase inhibitor isobutyl-
methylxanthine (Supplementary Fig. 9).
Increased NE-stimulated EE in p110αDEL mice. Adrenergic
stimulation of adipose tissue results in the recruitment of ‘brown-
like’ (beige or brite) adipocytes in WAT31. In order to further
investigate the effect of p110α inhibition in the adipose tissue
in vivo, we administered CL316,243, a β3-AR-speciﬁc agonist,
to 18-week-old mice daily for a period of 5 days. As shown in
Fig. 6a, administration of CL316,243 increased the mRNA
expression of Ucp1 and other thermogenic genes, markers of
brown and beige adipocytes, speciﬁcally in the inguinal WAT
of p110αFLOX and p110αDEL mice. Increased expression of Ucp1
mRNA was accompanied by increased protein levels as deter-
mined by immunoblot analysis (Fig. 6b, c and Supplementary
Fig. 10) and immunohistochemistry (Fig. 6d). In line with the
above documented increase in adrenergic signalling in the sub-
cutaneous WAT of p110αDEL mice, a higher expression of all
these markers was observed in the inguinal WAT of p110αDEL
compared to p110αFLOX mice. This suggests that inactivation of
p110α potentiates adrenergic signalling in vivo and increases
recruitment of beige adipocytes upon adrenergic stimulation of
subcutaneous adipose tissue.
To complete the physiological phenotypic analysis of p110αDEL
mice, we performed indirect calorimetry to determine EE under
free-living conditions, as well as in response to catecholamine
stimulation. As shown in Fig. 6e, f, EE and respiratory exchange
ratio were similar between approximately 1-year-old p110αFLOX
and p110αDEL mice under free-living conditions. These experi-
ments were performed in weight-matched groups of mice to
avoid the confounding effects of different metabolic mass. No
differences in water and food consumption or in loss of body
weight over the time course of the experiment were observed
between the genotypes (Fig. 6g). However, injection of norepi-
nephrine into unconscious mice measured at thermoneutrality
(30 °C) showed a signiﬁcantly increased EE in p110αDEL mice
compared to p110αFLOX littermates (Fig. 6h, i). p110αDEL mice
also tended to display a slightly higher basal EE, which was
consistent with their higher basal glucose turnover during the
Fig. 4 Inactivation of p110α potentiates β-adrenergic signalling selectively in iWAT. a, b Explants of inguinal (iWAT) (a) and visceral (vWAT) (b) white
adipose tissue were isolated from 1-year-old p110αDEL and p110αFLOX littermates and stimulated ex vivo with 1 μM isoproterenol (ISO) in the presence
or absence of the p110α inhibitor A66 (2 μM) for 20min, followed by tissue homogenisation and immunoblot analysis of phosphorylation of HSL, perilipin
and CREB. Phosphorylation of perilipin was assessed using phospho-PKA substrate antibodies. Representative immunoblots are shown. Graphs show
quantitative data pooled from n= 4 (pHSL) and n= 3 (pCREB, p-Perilipin) independent experiments. c Lipolysis in explants from 1-year-old male mice
(n= 3 per genotype) assessed as glycerol release over 30min following stimulation with 1 μM ISO in the presence or absence of 2 μM A66. d cAMP
levels measured by ELISA in explants from approximately 1-year-old male mice (n= 4 per genotype) stimulated with 1 μM ISO in the presence or
absence of 2 μM A66 for 20min. e Inhibition of p110α potentiates adrenergic signalling in hMADS cell-derived adipocytes stimulated with non-selective
(ISO isoproterenol, NE norepinephrine) or β3-selective (CL, CL316,243; YM, YM178) β-AR agonists at 1 μM. Quantitative data from n= 8 for basal−/
A66−/ISO−/ISO+ A66-treated, n= 7 for NE−/NE+ A66-treated, n= 4 for CL−/CL+ A66− and YM−/YM+ A66-treated independent experiments
and a representative immunoblot are shown in (e). Data are presented as mean ± SEM. Statistical analyses: one-way ANOVA with Bonferroni’s multiple
comparisons test (a–d) and paired two-tailed t test (e). *p < 0.05; **p < 0.01; ***p < 0.001
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clamp studies (Fig. 1f), but this did not reach statistical
signiﬁcance. The weights of all the mice were very similar
(Fig. 6j), whereas basal EE was 10% larger in p110αDEL mice,
suggesting that changes in EE were not simply a product of
changes in body weight and therefore metabolic mass. These
ﬁndings are consistent with the enhanced β-adrenergic signalling
in isolated adipose tissue explants from p110αDEL mice (Fig. 4
and Supplementary Fig. 6).
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Reduced age-dependent fat accumulation in p110αDEL mice.
We generated cohorts of p110αFLOX and p110αDEL littermates
and monitored their weight gain over time. As shown in Fig. 7a,
b, p110αDEL mice were born with a body weight similar to that of
p110αFLOX littermates. However, their growth curves started to
diverge at around 8 months of age and p110αDEL mice did not
accumulate as much weight as p110αFLOX littermates with age.
More speciﬁcally, the average weight of p110αDEL mice for the
period between 8–26 months of age was 7 and 8% lower for male
and female mice, respectively, compared to their p110αFLOX lit-
termates. Gonadal WAT and interscapular BAT weights were also
reduced in p110αDEL mice at 1.5 years of age, whereas BAT
masses normalised to body weight were similar in 2-year-old
mice, indicating a slower degeneration rate in BAT of p110αDEL
mice (Fig. 7c). Assessment of food intake in 1-year-old mice
showed no signiﬁcant differences in food intake between
p110αDEL and p110αFLOX littermates (Fig. 7d, e), except for the
tendency of p110αDEL male mice to consume slightly more
food (Fig. 7e), demonstrating that the weight difference between
the two genotypes was not due to different levels of food con-
sumption. Therefore, the increased catecholamine-stimulated
EE documented in our physiological studies described above
could be reducing fat accumulation over the life course in
p110αDEL mice.
Discussion
Metabolism is an essential process for all organisms and, like
many other biological processes, is adversely affected by ageing.
However, this relationship is also valid in the inverse direction in
that metabolic deterioration accelerates the rate of ageing in a
vicious cycle. In fact, glucose and lipid homoeostasis are emerging
as key determinants of the rate of ageing in a diverse range of
animal organisms. Consistent with this, genetic and pharmaco-
logical interventions affecting signalling pathways that regulate
metabolism, notably the IIS, mTOR and AMPK pathways, have
been shown to affect the lifespan of various organisms32. The fact
that downregulation of essential signalling pathways, such as IIS
and mTOR, exerts beneﬁcial effects is seemingly paradoxical. In
the context of metabolism, the gross phenotypic effects of inac-
tivation of these pathways are in many cases initially adverse,
consistent with the importance of these pathways, and beneﬁcial
effects emerge only later in life. It is therefore essential that
longitudinal studies are conducted in model organisms in order
to assess the long-term effects of such interventions and to
decipher the molecular mechanisms underlying these beneﬁcial
effects. These insights will help to reconcile the paradox of ben-
eﬁcial effects ensuing from the downregulation of essential
metabolic pathways.
Here, we report the ﬁndings of a longitudinal metabolic study
in mice that characterised the effects of adipose tissue-speciﬁc
deletion of PI3K p110α, the partial global inactivation of which
has been shown to confer a beneﬁcial effect later in life and to
moderately increase lifespan in mice12. We found that adipose
tissue-speciﬁc inactivation of p110α potentiated adrenergic sig-
nalling, speciﬁcally in subcutaneous white adipose tissue and in
brown adipose tissue. The molecular mechanism underlying this
effect appears to involve engagement of p110α in catecholamine-
stimulated Akt phosphorylation, which in turns activates phos-
phodiesterase and degradation of cAMP. Deletion of p110α
reduced catecholamine-induced PDE activation thus enhancing
cAMP-mediated signalling. The signiﬁcance of cAMP-mediated
signalling in thermogenic conversion of white adipose tissue has
recently been demonstrated by knockout of PDE3B shown to
promote browning of epididymal white adipose tissue33.
The potentiating effect on adrenergic signalling observed upon
p110α inactivation was modest and most likely for this reason
insufﬁcient to confer protection from weight gain during high-fat
feeding. However, glucose uptake by BAT was higher in
p110αDEL mice fed a high-fat diet, despite their similar insulin
sensitivity with p110αFLOX mice. This increased glucose uptake
from BAT likely explains the normal glucose tolerance in the face
of systemic insulin resistance documented over ageing of
p110αDEL mice. Moreover, p110αDEL mice did not accumulate as
much fat as p110αFLOX littermates upon ageing, which is arguably
a more physiological type of metabolic stress than high-fat
feeding, demonstrating that the modest effect of p110α deletion
on adrenergic signalling is sufﬁcient to confer a beneﬁcial effect
under physiological conditions. Indeed, there is substantial evi-
dence demonstrating that ageing diminishes the sensitivity of
adrenergic stimulation to reduce EE in humans34,35 as well as in
rodents36. In this regard, p110α inactivation could be counter-
acting the negative impact of ageing via regulating adrenergic
signalling in the adipose tissue and in particular in BAT where it
increased levels of UCP1.
Recently, another study reported a phenotype of adipose tissue-
speciﬁc p110α deletion using the aP2–Cre line37. The reported
phenotype is fundamentally different to the phenotype described
here and includes a decrease in thermogenic capacity of the
adipose tissue, as a result of downregulation of UCP1 and con-
sequent development of obesity and liver steatosis. The reason
for this striking discrepancy could be related to the different
Fig. 5 Mechanisms of adrenergic signalling enhancement by p110α inhibition. a β-AR stimulation induces p110α dependent Akt activation. Immunoblot
analysis of Akt phosphorylation induced by treatment with 1 μM isoproterenol in the presence or absence of 2 μM A66 in iWAT and vWAT explants
isolated from 38-week-old male p110αFLOX mice. Graphs show quantitative data from iWAT of three mice and vWAT of two mice. A representative
immunoblot is shown. b–e Inhibition of p110α potentiates β-adrenergic signalling in immortalised BAT-derived adipocytes (b) and BAT explants (c).
Immunoblot detection of NE-stimulated (1 μM for 20min) HSL (S660), perilipin and p38MAPK (T180/Y182) phosphorylation in lysates of BAT-derived
adipocytes (b) or isoproterenol (ISO)-stimulated (1 μM for 20min) BAT explants (c). Representative immunoblots and graphs showing average data
from three (n= 3) cell pools or explants isolated from individual p110αFLOX mice are shown. d NE-stimulated (1 μM for 10min) Akt (T308) phosphorylation
in the presence of inhibitors against PI3K p110α (A66, 2 μM) and p110β (TGX221, 1 μM) and EPAC (ESI09, 10 μM). A representative blot and data
from three (n= 3) BAT-derived cell pools isolated from different p110αFLOX mice are shown. e Phosphodiesterase activity measured in lysates of NE-
stimulated (1 μM for 20min) BAT-derived cell pools (n= 3 per genotype) isolated from individual p110αFLOX and p110αDEL mice in the presence or absence
of p110α inhibitor (A66, 2 μM) or EPAC inhibitor (ESI09, 10 μM). f Role of PI3K p110α in insulin- and β-adrenergic receptor-stimulated pathways in
adipocytes. Upon activation of the Insulin Receptor (IR), PI3K p110α promotes activation of phosphodiesterase (PDE) through phosphorylation by Akt (1).
p110α-dependent and Akt-mediated activation of PDE also occurs upon β-AR stimulation, possibly through EPAC activation, concomitantly with activation
of adenylylcyclase (AC) (2). According to scheme, inhibition of p110α reduces energy storage and fat mass increase through the insulin pathway and
promotes thermogenic energy expenditure and leanness through the β-AR pathway. Data are presented as mean ± SEM. Statistical analysis: one-way
ANOVA with Tukey’s multiple comparisons test (a); paired two-tailed t test (b, c); one-way ANOVA with Bonferroni’s multiple comparisons test (d, e).
*p < 0.05; **p < 0.01; ***p < 0.001
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conditional p110α alleles or the different Cre lines (aP2–Cre
versus adiponectin–Cre) used in these two studies. Also, potential
differences in the level of p110α deletion could critically deter-
mine the nature of the ensuing phenotypes. In the present study,
we documented a reduction in p110α protein levels of approxi-
mately 70–90%, depending on the tissue. However, it is likely that
higher levels of p110α deletion could result in more severe insulin
resistance, of which the negative impact would outweigh the
potential beneﬁts. Nevertheless, the phenotype described in the
present study is consistent with the beneﬁcial metabolic effects
of deletion of the IR in the adipose tissue of FIRKO mice9 as well
as with the recent demonstration that administration of a dual
p110α/δ PI3K inhibitor protects mice and monkeys from diet-
induced obesity and metabolic syndrome38, an effect more
recently shown to be largely recapitulated by administration of a
p110α selective inhibitor39. In the FIRKO mice, an increase in
oxidative metabolism in the adipose tissue was reported40, and
in the latter model, PI3K inhibition was shown to increase the
levels of UCP1 expression and fuel oxidation in BAT41, in line
with our ﬁndings.
The physiological importance of adrenergic signalling in the
development of age-related obesity has recently been highlighted
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by the demonstration that inﬂammatory macrophages reduce
adrenergic output by degrading catecholamines in the adipose
tissue42,43. An important implication of the present study is that
potentiation of adrenergic signalling in adipose tissue could be a
promising therapeutic approach to promote adipose tissue
browning and increased thermogenic EE, processes which have
been pursued in the therapy of obesity44,45. The use of β3-AR
agonists as potential therapeutics for obesity and type-2 diabetes
has been pursued intensively in the recent past, but lack of efﬁ-
cacy or side effects (mainly due to adrenergic stimulation of the
cardiovascular system) have prevented translation to clinical
application46. It is tempting to speculate that concomitant
administration of a p110α inhibitor could potentiate the effect of
β3-adrenergic agonists, increasing their efﬁcacy and their safety
proﬁle by reducing the effective doses, thus avoiding the side
effects of cross-activation of other types of β-adrenergic receptors
in other organs. YM178 (Mirabegron), a human β3-AR selective
agonist, which is clinically approved for other indications, has
recently shown efﬁcacy in activation of human BAT47. Also, as
mentioned above, administration of a PI3K inhibitor reversed
diet-induced obesity in mice and monkeys, providing proof-of-
principle of the utility of PI3K inhibitors in the context of
metabolic disease treatment38. Moreover, a number of p110α
inhibitors are undergoing clinical trials in oncology. Taken
together, these suggest that testing combinations of p110α inhi-
bitors and β3-adrenergic agonists in the treatment of obesity is a
realistic possibility.
Finally, the present work provides an example of how an
intervention that negatively affects an essential signalling path-
way, such as the IIS pathway, can at the same time act beneﬁcially
to mitigate the adverse effects, thus reconciling the insulin
paradox at the mechanistic level.
Methods
Mouse strains and maintenance. To generate mouse lines with adipose tissue-
speciﬁc deletion of PI3K p110α, mice with conditionally targeted p110α alleles
Fig. 6 p110αDEL mice display increased catecholamine-stimulated energy expenditure. a mRNA-expression levels of brown adipocyte markers in adipose
tissues isolated from 18-week-old p110αDEL and p110αFLOX littermate male mice (n= 4 per genotype) following intraperitoneal administration of the β3-AR
selective agonist CL316,243 (1 mg per kg per day) over ﬁve consecutive days. RNA was extracted from inguinal and epididymal adipose tissues and mRNA
expression of Ucp1, Cidea, Pgc1a, Deiodinase 2 (Dio2) and Elovl3 was analysed by quantitative PCR. b UCP1 protein expression detected by immunoblot
analysis (blot shown in Supplementary Fig. 10) in iWAT from the same mice as in (a) (n= 4 per genotype). c, d Immunoblot analysis (c) and
immunohistochemical detection (d) of UCP1 protein expression in iWAT of 6-week-old male mice injected with CL316,243 as in (a) (ns non-speciﬁc band).
Scale bar: 50 μm. e Raw energy expenditure of approximately 1-year-old p110αFLOX and p110αDEL female mice measured for 48 h at room temperature.
f Respiratory exchange ratio (RER) for the 48 h calorimetry run. g Water intake (WI), food intake (FI), change in body weight (dBW) and average
body weight (BW) for the 48 h of the calorimetry run. h–j Norepinephrine (NE)-stimulated energy expenditure (EE). h Energy expenditure measured in
unconscious mice housed at 30 oC prior to (basal) and after injection with 0.5 mg kg−1 NE. Bars are averages of three stable readings for baseline
prior to injection. NE-stimulated is the average of the three largest readings recorded. i Graph showing the effects of NE injection on energy expenditure
with time. j Body weights of the mice used at the time they were analysed. e–g n= 8 mice per genotype; h–j, n= 6 p110αFLOX and 7 p110αDEL mice.
Data are presented as mean ± SEM. Statistical analysis: one-way ANOVA with Bonferroni’s multiple comparisons test (a); unpaired two-tailed t test (h, i).
*p < 0.05; **p < 0.01
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Fig. 7 p110αDEL mice accumulate less weight with age. a, b Body weight gain over time in female (a) and male (b) p110αDEL and p110αFLOX mice. The
average body weight of each group of mice between 8 and 26 months of age were compared by unpaired t test. n= 66 per genotype for male; n= 76
p110αFLOX and 58 p110αDEL for female. c Epididymal WAT and interscapular BAT mass of 1.5- and 2-year-old male mice. n= 10 per genotype for WAT; n=
8 per genotype for BAT. d Food intake of approximately 1-year-old mice. Each data point represents an average measurement from a single cage. Female
mice (29 p110αFLOX and 20 p110αDEL) were distributed in 10 cages per genotype (n= 10) and male mice (22 p110αFLOX and 24 p110αDEL) mice were
distributed in 12 cages per genotype (n= 12). Data are presented as mean ± SEM. Statistical analysis: unpaired two-tailed t test. *p < 0.05; **p < 0.01
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(p110αFLOX)13 were crossed with transgenic mice expressing a Cre recombinase
under the control of the adiponectin promoter (Adipoq–Cre)14. Both lines were
in the C57BL6/J background. Experimental mice were littermates produced from
crosses of Adipoq–Cre (+) p110αFLOX mice with Adipoq–Cre (−) p110αFLOX
mice. Mice were housed in individually ventilated cages under a 12 h light/12 h
dark cycle at constant temperature (20–23 °C) with ad libitum access to food and
water and were fed a standard diet (2018, 18% Protein Rodent diet, Harlan Teklad)
or a high-fat diet (45% calories from fat; 58V8, TestDiet).
Maintenance and differentiation of hMADS cells. hMADS-3 cells isolated form
the prepubic fat pad of a 4-month-old male48 were maintained in DMEM supple-
mented with 10% foetal bovine serum and 2.5 ngml−1 human ﬁbroblast growth
factors. Adipocyte diffentiation was induced 24 h postconﬂuence by replacing
maintenance medium with differentiation induction medium consisting of DMEM/
Ham’s F12 (1:1) supplemented with 5 μgml−1 human insulin, 10 μg/ml−1 human
transferrin, 0.2 nM 3,3′,5-Triiodo-l-thyronine (T3), 1 μM rosiglitazone, 100 μM iso-
butylmethyxanthine (IBMX) and 1 μM dexamethasone. Three days later, the medium
was replaced with differentiation induction medium without IBMX and dex-
amethasone. Adipocytes were used in experiments upon completion of differentiation,
typically 5–7 days after induction.
Isolation, immortalisation and differentiation of brown pre-adipocytes.
Interscapular BAT was isolated from three p110αFLOX and three p110αDEL 5-week-
old male mice, minced with ﬁne scissors and digested with 1 mgml−1 collagenase
for 1 h at 37 °C. Mature adipocytes were separated from the stromal vascular
fraction (SVF) by centrifugation at 250g for 5 min. Pellets containing the SVF were
seeded in 6-well cell culture dishes in DMEM supplemented with 10% foetal bovine
serum and transduced with retroviruses carrying a plasmid encoding SV40 Large T
antigen (pBabe-puro-SV40LT, Addgene plasmid no 14088). Transduced cells were
selected with puromycin (2 μg ml−1) for 2 weeks. Adipocyte differentiation was
induced by treating conﬂuent cell monolayers with 1 μg ml−1 insulin, 1 μM dex-
amethasone, 0.5 mM isobutylmethyxanthine (IBMX), 1 μM rosiglitazone and 1 nM
3,3′,5-Triiodo-l-thyronine (T3). After 48 h, the medium was replaced with fresh
DMEM supplemented with 10% foetal bovine serum. Cell monolayers were used in
experiments upon completion of differentiation, typically 1 week after induction.
Body weight and food intake analysis. Body weight was measured monthly from
4 weeks of age onwards. For food intake assays, mice were housed in small groups
of 2–3 individuals and allowed to acclimatise for 2 days before the study. Food
pellet and mouse body weights were measured at the beginning and end of a 3-day
measurement. Results are expressed as cumulative food intake (grams of chow per
kg of body weight per 3 days).
Blood metabolic biomarkers. Blood samples from fed or fasted (16 h) mice were
collected from the tail vein with heparinized capillaries and then spun in a
benchtop microcentrifuge for 5 min to pellet blood cells. Plasma was transferred to
a fresh tube and stored at −80 °C until further use. Mouse plasma hormone and
cytokine levels were determined by ELISA kits: Insulin, leptin and adiponectin
(Crystal Chem); TNFα and Interleukin-6 (PeproTech). Triglycerides, free fatty
acids and cholesterol in plasma were determined using the Inﬁnity Triglycerides
Liquid stable Reagent (TR22421; Thermo Scientiﬁc), NEFA-HR(2) kit and
Cholesterol Liquid (Wako, Richmond, VA), respectively.
Glucose and insulin tolerance tests. GTTs and ITTs were performed on mice at
different ages, fasted for 16 or 5 h, respectively. Blood glucose levels were deter-
mined at several time points (up to 120 min) after intraperitoneal injection of a
glucose solution (2 g per kg of body weight) or human insulin (Actrapid, Novo
Nordisk) (0.75–2 U per kg of body weight). Blood glucose concentrations were
measured in tail vein blood samples using a Contour XT glucometer (Bayer).
Hyperinsulinemic–euglycemic clamps. Hyperinsulinemic–euglycemic clamps
were performed in anaesthetised animals on thermally controlled pads to maintain
their core body temperature. Animals were anesthetized by intraperitoneal injec-
tion of a combination of 6.25 mg per kg acetylpromazine, 6.25 mg kg−1 midazolam
and 0.31 mg kg−1 fentanyl. An infusion needle was placed into the tail vein and
6,6-D2 D-glucose (Goss Scientiﬁc) was infused at a rate of 100 nMmin−1 for
80 min to achieve steady-state levels and blood samples collected on blood spot
cards (Whatman 903 Protein Saver Card, SLS) to determine basal glucose turnover.
Thereafter, insulin (Actrapid; Novo Nordisk) was infused at a constant rate of
0.91 mUmin−1 after a bolus dose of 16.5 mU and 6,6-D2 D-glucose infusion rate
was increased to 200 nMmin−1 to limit changes in enrichment levels of labelled
glucose in blood. A variable infusion of 12.5% D-glucose was used to maintain
blood glucose at euglycemic (basal) levels. Blood glucose was measured with an
AlphaTRAK2 glucometer (Abbott Animal Health) every 5–10 min and glucose
infusion adjusted accordingly. Steady state was reached after 70 min and blood
samples were collected on blood spot cards at 10-min intervals over 30 min to
determine steady-state enrichment levels of 6,6-D2 D-glucose. Blood samples for
serum were collected at the end of the basal infusion phase and at the end of the
hyperinsulinaemic phase for determination of FFAs and insulin levels during the
clamp. Mice were then killed by cervical dislocation and the organs removed
and frozen. Blood spots cards were extracted in 90% ethanol. Extracts underwent
aldonitrile-pentaacetate derivatisation and mass spectral analysis as described
in Supplementary Information. Insulin levels were determined by ELISA (Ultra
Sensitive Mouse Insulin ELISA Kit, Crystal Chem) and FFA levels were determined
enzymatically (HR Series NEFA-HR(2), WACO)
Tissue-speciﬁc glucose uptake. Tissue-speciﬁc glucose uptake was determined by
intraperitoneal administration of 2-[3H]-deoxyglucose (DG). Overnight fasted
mice were injected with 1 g per kg D-glucose spiked with 2-[3H]-DG (12 MBq [3H]-
DG (Perkin Elmer) per gram of D-glucose). Blood samples were collected from tail
vein at 0, 15, 30 and 60 min following glucose injection. At the end of the time
course, tissues were excised and snap frozen in liquid nitrogen. The 2-[3H]-DG
uptake into tissues was determined with the Ba(OH)2/ZnSO4 precipitation method.
Brieﬂy, 100 mg of tissue samples were homogenised in 1.5 ml (or 5 μl of plasma
were diluted in 0.5 ml) of 0.5% perchloric acid. Lysates were clariﬁed by cen-
trifugation in a benchtop microcentrifuge. One millilitre of the clariﬁed super-
natant was neutralised by addition of 50 ml each of 10% KOH and 1M potassium
phosphate buffer pH 7.0. 0.55 ml of the neutralised supernatant was transferred
to a scintillation vial (designated n). The remainder 0.55 ml was precipitated by
addition of 100 ml each of 0.3 N Ba(OH)2 and 0.3 N ZnSO4 and centrifugation at
16,000×g in a benchtop microcentrifuge. Totally, 0.6 ml of the supernatant was
transferred to a scintillation vial (designated p). Disintegrations per minute (dpm)
were measured in n and p aliquots by liquid scintillation counting. The difference
in dpm between n and p represents uptake of 2-[3H]-DG. Clearance of 2-[3H]-DG
and the metabolic index (Rg), as a measure of tissue-speciﬁc glucose uptake, were
calculated using the following equations:
Kg ¼ 2½ 3Htissue=AUC2½ 3HDGplasma;
Rg ¼ Kg ´Glucoseplasma;
where 2-[3H]-DGPtissue is the 2-[3H]-DG-6-Phosphate radioactivity in the tissue
in dpm per g of tissue weight, AUC 2-[3H]-DGplasma is the area under the plasma
2-[3H]-DG disappearance curve in dpm per ml per min and Glucoseplasma is the
average blood glucose concentration in millimolar during the glucose excursion49.
Protein extraction and immunoblot analysis. Mouse tissues were harvested and
ﬂash frozen in liquid nitrogen and then stored at −80 °C until further processing.
Samples were homogenised in a lysis buffer containing 50 mM Tris-HCl pH 7.4,
100 mM NaCl, 50 mM NaF, 5 mM EDTA, 2 mM EGTA, 40 mM beta-glycer-
ophosphate, 10 mM sodium pyrophosphate and 1% Triton X-100 and protease
inhibitors. Proteins were separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis and then transferred to PVDF membrane. A total of 5% non-fat
milk was used to saturate the membrane prior to incubation with primary anti-
bodies. p110α (cat. no. 4255, diluted 1:1000), p110β (cat. no. 3011, diluted 1:1000),
pT308 Akt (cat. no. 2965, diluted 1:1000), pS473 (cat. no. 4060, diluted 1:1000),
total Akt (cat. no. 9272, diluted 1:1,000), pS660 HSL (cat. no. 4126, diluted 1:1000),
total HSL (cat. no. 4107, diluted 1:1000), phospho-PKA substrate (cat. no. 9624,
diluted 1:1000), total perilipin (cat. no. 9349, diluted 1:1000), pS133 CREB (cat. no.
9191, diluted 1:1000), p T180/Y182 p38 MAPK (cat. no. 9215, diluted 1:1000) and
total p38 MAPK (cat. no 9212, diluted 1:1000) antibodies were from Cell Signaling
Technology (CST). UCP1 antibody was from Abcam (cat. no. 10,983, diluted
1:1000). p85 antibody (cat. no. 06-195, diluted 1:1000) was from Millipore. Vin-
culin antibody (cat. no. V9264, diluted 1: 10,000) was from Sigma. PDE3b antibody
(cat. no. STJ110746, diluted 1:1000) was from St. John’s Laboratory. Membranes
were then washed and incubated with HRP-conjugated, goat anti-Rabbit IgG
(DAKO, cat. no. P0448, diluted 1:2000) and developed using ECL reagent
(GE Healthcare) for radiographic ﬁlm detection of p110α. Band intensity was
quantiﬁed by ImageJ software. In all other cases, detection was performed with
ﬂuorescently labelled secondary antibodies (anti-mouse DyLight 800-conjugated,
Rockland, cat. no. 610-145-002, diluted 1:5000 and anti-rabbit Alexa-Fluor 680-
conjugated, Invitrogen, cat. no. A21076, diluted 1:5000), using an Odyssey CLx
infra-red scanner (LICOR). Detection and quantiﬁcation were performed using the
manufacturer’s software (Image Studio). Uncropped images of the most important
blots are shown in Supplementary Information.
Immunoprecipitation and PI3K assay. For immunoprecipitation and PI3K lipid
kinase assay, tissue lysates were prepared as described above. Immunoprecipi-
tation was performed by mixing lysates (2 mg of protein) with 2 μg IRS-1
antibody (Millipore, cat. no. 05-1085). Following overnight incubation at 4 °C,
immune complexes were captured by addition of protein-A-Sepharose beads
(GE Healthcare) and incubation for an additional 1 h. Bead-associated immune
complexes were subjected to lipid kinase assays. Lipid kinase assays were per-
formed in a total volume of 50 μl in a buffer containing 50 mM HEPES (pH 7.4),
100 mM NaCl, 1 mM dithiothreitol, 5 mM MgCl2, 100 μM ATP (plus 0.1 μCi of
[γ-32P]-ATP per assay) using 200 μg ml−1 phosphatidylinositol (Sigma) as a
substrate. Reactions were incubated at 25 °C for 20 min and terminated by
the addition of 100 μl of 0.1 M HCl and 200 μl of chloroform:methanol (1:1).
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The mixture was vortexed and the phases were separated by centrifugation at
10,000 × g for 2 min. The lower organic phase was spotted onto thin layer
silica (TLC) gel-60 plates (Merck), which had been treated with 1% oxalic acid,
1 mM EDTA in water:methanol (6:4). TLC plates were developed in a solvent
consisting of propanol-1:2 M acetic acid (13:7). Images of radiolabelled lipid
products were captured using a Fuji FLA-2000 phosphorimager and analysed
using ImageJ software.
UCP1 immunohistochemistry. Adipose tissues were ﬁxed in formalin for 24 h and
embedded in parafﬁn. Tissue sections were deparafﬁnised, subjected to antigen
unmasking (boiling in 10 mM sodium citrate pH 6 in a pressure cooker for 30
min), blocked with 5% bovine serum albumin (BSA) and incubated with UCP1
antibody (Abcam, cat. no. 10983) diluted 1:1000 for 16 h at 4 °C. Sections were then
incubated with SignalStain© Boost IHC Detection Reagent (Cell Signaling Tech-
nology, cat. no. 8114P) and immune complexes were visualised with SignalStain©
DAB reagent (Cell Signaling Technology, cat. no. 8059).
RNA extraction and qPCR. RNA was extracted from adipose tissue samples using
Triazol (Thermo Fisher) and reverse transcribed to cDNA using Qiagen Omnis-
cript RT kit according to the manufacturer’s instructions. Quantitative PCR
(qPCR) was performed using an ABI7900HT Fast Real Time PCR detection system
and Power SYBR-Green PCR Master Mix (ABI). Relative gene expression was
quantiﬁed using the 2−ΔΔCt method. Mouse ribosomal protein S18 (rps18) was
used as a loading control. A list of primers used in the present study is given in
Supplementary Table 1.
Lipolysis and cAMP levels in adipose tissue explants. Adipose tissue explants
were adjusted to approximately 100 mg of weight and then minced with ﬁne
scissors. Explants were incubated in serum-free DMEM supplemented with 0.2%
(w/v) fatty acid-free BSA for 2 h at 37 °C in 5% CO2 incubator then transferred
to Kreb’s–Riger’s buffer (30 mM Hepes pH 7.4, 10 mM NaHCO3, 120 mM NaCl,
4 mM KH2PO4, 1 mM MgSO4, 0.75 mM CaCl2) supplemented with 0.2% fatty
acid-free BSA and 10 mM glucose and incubated for an additional hour. Inhibitors
were added for the last 15 min of the incubation. Lipolysis was stimulated by
addition of 1 μM Isoproterenol or Norepinephrine-L-bitartate (Sigma). Totally,
50 μl of medium was removed 30 min following stimulation and glycerol content
was determined using Glycerol Reagent and Glycerol Standard (Sigma). For
determination of intracellular cAMP levels tissue explants were processed, incu-
bated and stimulated as above. Explants were collected 20 min following adrenergic
stimulation, frozen in dry ice and kept in −80 °C until further processing. Samples
were homogenised in 0.5 ml of 0.1 N HCl using a mechanical homogeniser.
Homogenates were clariﬁed by centrifugation for 5 min in a benchtop refrigerated
microcentrifuge. Supernatants were diluted 1 in 4 with cAMP ELISA buffer and
the cAMP content was determined with a cyclic AMP Select ELISA kit (Cayman,
cat. no. 501040).
Phosphodiesterase activity assay. BAT-derived adipocytes were lysed in a buffer
containing 20 mM Hepes-NaOH (pH 7.4), 0.5 mM EDTA, 2 mM MgCl2, 0.1%
Triton X-100, 0.5 mM DTT, 1 mM EGTA, 1 μM microcystin-LR and protease
inhibitors. Lysates were brieﬂy sonicated using a probe sonicator and were desalted
using Zeba Spin desalting columns, 7 kD molecular weight cut-off (Thermo Sci-
entiﬁc, cat. no. 89882), equilibrated in PDE assay buffer. Desalted lysates (15 μg
protein) were assayed for phosphodiesterase activity using a kit from Abcam
(cat. no. ab139460) according to the manufacturer’s instructions.
Indirect calorimetry. EE and norepinephrine-induced thermogenesis were mea-
sured using a Metatrace gas analyser (Creative Scientiﬁc, UK). The gas analyser
uses a paramagnetic oxygen analyser and an infra-red CO2 sensor to measure
oxygen and carbon dioxide concentrations. The analyser operates in push mode
with airﬂow to each chamber controlled by a mass ﬂow controller set to ﬂow 400
ml per min. Cages were multiplexed to the analyser, with four cages being read by
each analyser. For free-living EE cages were sampled for 30 s every 11 min, with a
90 s washout period between each chamber. EE was calculated from the VO2
and CO2 according to the modiﬁed Weir equation: EE (J min−1)= 15.818 × VO2
(ml min−1)+ 5.176 × VCO2 (ml min−1). For NE-induced thermogenesis, mice
were anesthetized with sodium pentobarbital (90 mg kg−1) and placed in a 30 °C
chamber. Mice were injected with 0.5 mg NE per kg. The dose of NE gave an
average increase in EE of ~40% over the basal EE, while normal maximal ther-
mogenic capacity experiments were for mice acclimated to a similar temperature
a 160% increase would be expected50. Therefore, the applied NE dose fulﬁlled
the requirement of being a sub-maximal dose and could potentially allow
detection of changes in sensitivity to NE, not just changes in brown adipose tissue
thermogenic capacity.
Statistical analysis. Data are presented as mean ± standard error of the mean
(SEM). Statistical analyses were performed with GraphPad Prism 8. Speciﬁc tests
are detailed in the ﬁgure legends.
Study approval. All experimental procedures complied with the UK Home Ofﬁce
Animals (Scientiﬁc Procedures) Act 1986 and were performed with the approval
of the UCL Animal Welfare and Ethical Review Body.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the ﬁndings of this study are included in this published article and
its Supplementary Information ﬁles. All other relevant data are available from the
corresponding author upon reasonable request.
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